Key facts
- It has raised $18.6M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Zhongshan Finance Investment, Fuho Capital, Zhongshan Xiwan Investment Holding Development, CuiHeng Group, Bison Capital Financial Holdings — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Hengsai Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Hengsai Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hengsai Bio
Developer of personalized dendritic cell tumor vaccines intended to provide new treatment approaches and strategies for relapsed and refractory tumors. The company's vaccines focuses on on the field of tumor immunotherapy and has been developed to treat relapsed and refractory tumors, chronic viral infections, autoimmune diseases and other diseases that are in urgent need of effective clinical treatments, enabling healthcare professionals to administer treatments and vaccines with safety, efficiency, and convenience in mind.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Ownership
- Privately Held (backing)
Hengsai Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hengsai Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hengsai Bio in its N-PORT filings yet. We sweep new filings monthly.